CD274 and cancer: These findings suggest that reducing PD-L1 expression in cancer cells through WCC and ECC treatment may enhance the effectiveness of anti-cancer treatments by inhibiting the PD-1/PD-L1 immune checkpoint and maintaining T cell function.